PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-63.84%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-88.24%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-87.91%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-87.91%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-63.84%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
10Y OCF/share CAGR at 50-75% of GNPX's 91.62%. Martin Whitman might fear a structural deficiency in operational efficiency.
53.61%
5Y OCF/share CAGR at 50-75% of GNPX's 96.48%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
53.61%
3Y OCF/share CAGR at 50-75% of GNPX's 96.26%. Martin Whitman would suspect weaker recent execution or product competitiveness.
35.25%
Below 50% of GNPX's 99.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
35.25%
Below 50% of GNPX's 96.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
35.25%
Below 50% of GNPX's 96.48%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Positive asset growth while GNPX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-28.60%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
50.95%
Debt growth of 50.95% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
47.25%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.